Company Directory

Global viral vector CDMO for cell and gene therapy

Oxford Biomedica (OXB) is a global contract development and manufacturing organisation specialising in viral vectors for cell and gene therapy. The company provides lentiviral, adeno-associated virus (AAV), and adenoviral vector development and manufacturing services from early-stage process development through to commercial-scale GMP manufacture. OXB is headquartered in Oxford and operates manufacturing sites across Oxfordshire, France, and the United States.

Automated instruments and consumables for cytogenetic and genomic laboratories

ADS Biotec develops and manufactures automated laboratory instruments and consumables for cytogenetic, pathology, and molecular biology applications. Its product range includes robotic systems for chromosome harvesting and spreading, HPLC columns for mRNA purification, and custom buffer and reagent manufacturing services. The company serves research, diagnostic, and clinical laboratories across more than 30 countries. ADS Biotec is a subsidiary of ADSTEC, a Japanese life sciences instrumentation group.

Modular automated RNA manufacturing platform

Centillion is a UK biotech company whose platform integrates synthesis, purification, and formulation stages using continuous flow chemistry to produce mRNA and self-amplifying RNA at research and production scale. The platform supports process development through to regulatory-ready CMC packages and is available as a service, under licence, or through joint development programmes. First GMP installation was completed at Quotient Sciences in Alnwick in 2024.

Next-generation lipid nanoparticle platform for RNA vaccines and medicines

NeoVac is a biotechnology company developing a next-generation lipid nanoparticle platform to improve the delivery of RNA vaccines and therapeutics. Its library of fully biodegradable, tissue-targeted LNPs addresses limitations of first-generation formulations, offering enhanced thermostability, multiple routes of administration, and improved safety profiles. Applications span infectious disease vaccines, oncology, and broader RNA medicine programmes. NeoVac has advanced a Phase I mRNA vaccine candidate in UK volunteers.

Cell-free enzymatic synthesis platform for biotherapeutic discovery

Newcleic is a biotech developing cell-free, enzymatic synthesis methods and systems to accelerate biotherapeutic discovery and manufacture. The platform uses cell-extracted or purified enzymatic machinery to produce proteins and nucleic acids from genetic templates without the need for live cell engineering, enabling faster design-build-test cycles. Applications include antibody-drug conjugates, RNA therapeutics, and other biologics where rapid, cell-free production offers manufacturing and discovery advantages.

GMP-grade cell-free synthetic DNA for genetic medicines

4basebio is a biotechnology manufacturing company producing GMP-grade synthetic DNA for use in cell and gene therapies, mRNA vaccines and genome editing applications. Using an enzymatic, cell-free synthesis process, the company manufactures application-specific linear DNA constructs that overcome the purity and scalability limitations of conventional plasmid-based systems. 4basebio holds MHRA GMP certification for clinical-grade manufacture and also develops non-viral nanoparticle delivery systems for genetic medicine applications.

Integrated chemistry and development CRO for small molecules

CatSci is a Cardiff-headquartered contract research organisation providing integrated chemistry, analytical, and development services to biotech and pharmaceutical companies. Founded in 2010 by former AstraZeneca scientists, the company offers process chemistry, analytical development, solid-state and preformulation science, HPAPI development, and preparative purification across the drug development lifecycle. Capabilities have expanded to include oligonucleotide and peptide development. CatSci operates across 14 laboratories in Cardiff, Nottingham, and Strasbourg, serving over 100 biotech and pharma partners globally.

Contract synthesis of custom and modified oligonucleotides

ATDBio is a UK-based contract oligonucleotide synthesis company specialising in chemically modified DNA and RNA oligonucleotides for therapeutic and diagnostic applications. Its services span discovery through preclinical scale, encompassing antisense oligonucleotides, siRNA, aptamers, and diagnostic probes, with a broad range of backbone, sugar, and terminal modifications including LNA, phosphorothioate, and GalNAc conjugates. Laboratories are ISO 9001 certified and based at the University of Southampton and Oxford Science Park.

Enzymatic DNA synthesis for pharmaceutical and biotechnology research

Camena Bioscience is a synthetic biology company that develops and supplies enzymatic gene synthesis technology to pharmaceutical and biotechnology customers. Its multi-enzymatic approach to DNA synthesis offers substantially improved accuracy and access to longer, more complex sequences compared to conventional phosphoramidite chemistry, without the need for codon optimisation. The company supplies synthetic genes and synthesis reagents to customers in drug discovery, antibody engineering, and RNA therapeutics, and also offers in-house synthesis capabilities for proprietary sequences.

Gene therapy and biologics CDMO with cGMP manufacturing in Liverpool

Pharmaron Biologics (UK) Ltd is a contract development and manufacturing organisation specialising in biologics and cell and gene therapy, operating from cGMP biomanufacturing facilities in Speke, Liverpool. The site offers end-to-end services spanning plasmid design, cell line development, viral vector process development, clinical manufacture and advanced analytical characterisation, with particular expertise in AAV gene therapies. It serves gene therapy developers, vaccine developers and biopharmaceutical companies globally.

Integrated bioprocessing platform for biologics development and manufacture

Biologic Technologies is a developer of intelligent bioprocessing platforms for biologics development and manufacturing. Its platform integrates complete biological workflows into a single automated device, combining precision fluid handling, in-line process analytics, and AI-driven optimisation. Application-specific cartridges support workflows including RNA and mRNA manufacturing, cell line development, fermentation, and cell and gene therapy production. The platform is designed to be accessible across scales, from early-stage process development through to cGMP manufacturing.

mRNA vaccine manufacturer and R&D partner

Moderna is a company developing and manufacturing mRNA-based medicines and vaccines across infectious disease, oncology and rare disease. Its UK Innovation and Technology Centre, opened at Harwell in September 2025, is the first facility in the UK capable of onshore mRNA vaccine manufacturing, with capacity for up to 250 million doses annually. The site forms part of a ten-year strategic partnership with the UK government underpinned by over £1 billion in committed R&D investment.